<DOC>
	<DOCNO>NCT01284257</DOCNO>
	<brief_summary>The MORE Observational Study follow real-world renal transplant patient data resolution monitor , prospective clinical trial 5 year . In addition capturing detailed clinical data , study describes recent important change surveillance test drug therapy relate change short long-term outcome . Also , study measure patient compliance time detail rationale modification MPA dose maintenance regimen change episodes AR . The MORE study provide information era change transplant practice impact clinical outcome , new insight optimize regimen discrete patient subset new perspective optimal use MPA therapy .</brief_summary>
	<brief_title>Observational Registry Study Renal Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>18 year age old . The de novo recipient cadaveric live donor kidney transplant , within two week transplantation . Receiving mycophenolic acid ( MPA ) therapy either myfortic® CellCept® . Able provide inform consent . Able selfadminister ITAS compliance instrument ( 6 question ) . The recipient multiple organ graft prior nonkidney graft . Enrolled plan enroll investigational clinical trial . Not likely 5 year followup data available study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>EC-MPS</keyword>
	<keyword>MMF</keyword>
	<keyword>kidney transplant</keyword>
	<keyword>outcome</keyword>
	<keyword>mycophenolate sodium</keyword>
	<keyword>mycophenolic acid ( MPA )</keyword>
</DOC>